Literature DB >> 7024027

Lymphocytes from diabetics suppress insulin release in vitro.

C Boitard, M Debray-Sachs, A Pouplard, R Assan, J Hamburger.   

Abstract

The insulin response of isolated islet cells to glucose and theophylline in vitro was studied after incubation with lymphocytes. The test was employed to explore cell-mediated immunity in diabetics. A significant inhibition of insulin response to glucose and theophylline as compared to insulin release in a "basal" medium was found after incubation with blood lymphocytes from 21 out of 23 insulin-dependent diabetics (mean secretion index 18 +/- 18 versus 118 + 8 (SEM) % in control subjects). Most of the patients studied had associated autoimmune diseases: all of these displayed inhibition of insulin release. In six cases, the diabetes had a recent onset with no associated autoimmune disease: four of them displayed the same inhibition. No inhibition was found in the 26 control subjects and in seven non-insulin-dependent diabetics (mean secretion index 134 +/- 17 versus 145 +/- 23 (SEM) % in four control subjects). Lymphocytes inhibiting islet cell response were not cytotoxic against mouse fibroblasts. Twenty-two insulin-dependent diabetics showed islet cell antibodies to human and/or mouse pancreatic islets. However, an inhibition of insulin release was found with no detectable islet cell antibodies in one case, and the converse in two cases. Lymphocyte cytotoxicity to islet cells could play a role in the natural history of insulin-dependent diabetes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7024027     DOI: 10.1007/bf03216222

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  23 in total

1.  [Functional inhibition of isolated pancreatic cells, new technic for the detection of macrophage cytotoxicity].

Authors:  M Debray-Sachs; R Assan; D Bailey; J Hamburger
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1978-11-06

2.  Immunoassay of endogenous plasma insulin in man.

Authors:  R S YALOW; S A BERSON
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

3.  A lymphocyte cytotoxicity rebound phenomenon induced by enhancing sera.

Authors:  M Debray-Sachs; P E Soucy; J Hamburger
Journal:  J Immunol       Date:  1973-03       Impact factor: 5.422

4.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

5.  Pathologic anatomy of the pancreas in juvenile diabetes mellitus.

Authors:  W Gepts
Journal:  Diabetes       Date:  1965-10       Impact factor: 9.461

6.  Passive transfer of lymphocytes from diabetic man to athymic mouse.

Authors:  A S Serra; J R Farndon; B K Shenton; I D Johnston
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

7.  Islet-cell-surface antibodies in juvenile diabetes mellitus.

Authors:  A Lernmark; Z R Freedman; C Hofmann; A H Rubenstein; D F Steiner; R L Jackson; R J Winter; H S Traisman
Journal:  N Engl J Med       Date:  1978-08-24       Impact factor: 91.245

8.  Insulin-dependent diabetes: a disease of autoaggression.

Authors:  S W Huang; N K Maclaren
Journal:  Science       Date:  1976-04-02       Impact factor: 47.728

9.  Complement-mediated cytotoxic effects on pancreatic islets with sera from diabetic patients.

Authors:  H G Rittenhouse; D L Oxender; S Pek; D Ar
Journal:  Diabetes       Date:  1980-04       Impact factor: 9.461

10.  Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects.

Authors:  S A BERSON; R S YALOW; A BAUMAN; M A ROTHSCHILD; K NEWERLY
Journal:  J Clin Invest       Date:  1956-02       Impact factor: 14.808

View more
  20 in total

Review 1.  Molecular aspects of type 1 diabetes.

Authors:  M A Kelly; M L Rayner; C H Mijovic; A H Barnett
Journal:  Mol Pathol       Date:  2003-02

Review 2.  The differentiation of the immune system towards anti-islet autoimmunity. Clinical prospects.

Authors:  C Boitard
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

Review 3.  Mechanisms of autoimmunity in insulin-dependent diabetes mellitus.

Authors:  J F Bach
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

Review 4.  Disordered cellular immunity in type I diabetes of man and the BB rat.

Authors:  J B Buse; R F Rowley; G S Eisenbarth
Journal:  Surv Immunol Res       Date:  1982

5.  Immunologic factors in pathogenesis and treatment of human and animal diabetes.

Authors:  A Naji; W K Silvers; S T Bartlett; J Francfort; C F Barker
Journal:  World J Surg       Date:  1984-04       Impact factor: 3.352

6.  Functional and morphological modifications induced in rat islets by pentamidine and other diamidines in vitro.

Authors:  D Boillot; P in't Veld; P Sai; G Feutren; W Gepts; R Assan
Journal:  Diabetologia       Date:  1985-06       Impact factor: 10.122

7.  Islet cell surface antibodies from insulin-dependent diabetics bind specifically to pancreatic B cells.

Authors:  M Van De Winkel; G Smets; W Gepts; D Pipeleers
Journal:  J Clin Invest       Date:  1982-07       Impact factor: 14.808

Review 8.  The role of immunotherapy in type I diabetes mellitus.

Authors:  M E Geffner; B M Lippe
Journal:  West J Med       Date:  1987-03

9.  Cellular and humoural autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure.

Authors:  A V Zavala; L E Fabiano de Bruno; A I Cardoso; A H Mota; M Capucchio; E Poskus; L Fainboim; J C Basabe
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

10.  Pentamidine, a new diabetogenic drug in laboratory rodents.

Authors:  P Saï; D Boillot; C Boitard; M Debray-Sachs; G Reach; R Assan
Journal:  Diabetologia       Date:  1983-11       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.